Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2017-08-03 Interim / Quarterly Rep…
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2017
2017-08-03 English
FORM 4 SUBMISSION
Director's Dealing
2017-07-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 20, 2017, reporting the resignation of two board members and their roles in committees. The key section is Item 5.02, which specifically addresses the departure of directors or principal officers. The content focuses on changes in the company's board of directors and management, including resignations and related announcements. There are no financial statements or detailed financial data present, and the document is not an earnings release, annual report, or other financial report. Therefore, this filing fits the category of Board/Management Information (MANG). The document length is 3693 characters, which is consistent with a typical 8-K reporting management changes rather than a full report. Confidence is high due to the clear and explicit description of director resignations and no conflicting information.
2017-07-24 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 28, 2017, by Minerva Neurosciences, Inc. The key content is the announcement of an underwriting agreement for a public offering of common stock, including details about the number of shares, pricing, and underwriters. It also references press releases announcing the offering and its pricing. There are no financial statements or detailed financial results included, nor is this a full annual or quarterly report. The primary focus is on the company's capital raising activity through a stock offering. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 5934 characters, which is sufficient to contain substantive information about the financing event rather than just a brief announcement or a report publication notice.
2017-06-29 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, use of proceeds, risk factors, and company overview. It is a registration and offering document, not a financial report, earnings release, or management discussion. The presence of terms like 'Prospectus Supplement', 'Registration No.', 'offering price', 'underwriting discounts', and 'shares offered' clearly indicate this is a capital raising document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication announcement but a full prospectus supplement.
2017-06-29 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to an offering of common stock. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule related to prospectus supplements for securities offerings. The content focuses on the terms of the stock offering, company background, and related disclosures, which are typical of capital raising documents. There is no indication of financial statements, audit reports, earnings releases, or other report types. This document is clearly an update or supplement to a registration statement for a securities offering, which fits the category of Capital/Financing Update (CAP).
2017-06-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.